ADS · CUSIP 82686Q101 · who reports it, how much, and how much it matters to them
15 of the 720 hedge fund managers we track reported shares of Silence Therapeutics plc (Nasdaq: SLN) on Form 13F for 30 June 2026. Between them they reported USD 70m. The largest position belongs to Redmile Group, at USD 24m. The manager with the most riding on it is M28 Capital Management, where it is 2.4% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Redmile Group10 funds on PPLI.com | USD 24m | 1.6% |
| 2 | Citadel Advisors32 funds on PPLI.com | USD 15m | 0.0% |
| 3 | Millennium Management6 funds on PPLI.com | USD 10m | 0.0% |
| 4 | Balyasny Asset Management25 funds on PPLI.com | USD 6.7m | 0.0% |
| 5 | Great Point Partners2 funds on PPLI.com | USD 4.9m | 0.9% |
| 6 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 3m | 0.0% |
| 7 | Boothbay Fund Management2 funds on PPLI.com | USD 2.2m | 0.0% |
| 8 | Two Sigma Investments35 funds on PPLI.com | USD 1.3m | 0.0% |
| 9 | Squarepoint Ops7 funds on PPLI.com | USD 1.3m | 0.0% |
| 10 | M28 Capital Management1 fund on PPLI.com | USD 1.1m | 2.4% |
| 11 | Marshall Wace LLP84 funds on PPLI.com | USD 791,000 | 0.0% |
| 12 | Verdad Advisers6 funds on PPLI.com | USD 224,000 | 0.2% |
| 13 | Scientech Research2 funds on PPLI.com | USD 210,000 | 0.2% |
| 14 | Renaissance Technologies13 funds on PPLI.com | USD 186,000 | 0.0% |
| 15 | Persistent Asset Partners10 funds on PPLI.com | USD 167,000 | 0.1% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | M28 Capital Management | USD 1.1m | 2.4% |
| 2 | Redmile Group | USD 24m | 1.6% |
| 3 | Great Point Partners | USD 4.9m | 0.9% |
| 4 | Verdad Advisers | USD 224,000 | 0.2% |
| 5 | Scientech Research | USD 210,000 | 0.2% |
| 6 | Persistent Asset Partners | USD 167,000 | 0.1% |
| 7 | Boothbay Fund Management | USD 2.2m | 0.0% |
| 8 | Schonfeld Strategic Advisors | USD 3m | 0.0% |
| 9 | Balyasny Asset Management | USD 6.7m | 0.0% |
| 10 | Millennium Management | USD 10m | 0.0% |
Silence Therapeutics plc trades under the symbol SLN on the Nasdaq. Its CUSIP, the code used on Form 13F, is 82686Q101.
15 of the 720 hedge fund managers PPLI.com tracks reported Silence Therapeutics plc shares on Form 13F for 30 June 2026. The largest reported positions were held by Redmile Group (USD 24m), Citadel Advisors (USD 15m), Millennium Management (USD 10m), Balyasny Asset Management (USD 6.7m) and Great Point Partners (USD 4.9m).
15 managers in our coverage reported it, and between them they run 265 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
M28 Capital Management, where the position was 2.4% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Silence Therapeutics plc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.